Decode the names on the box, the trial acronyms in headlines and the mechanism words doctors use, so you can tell single-target drugs from dual or triple agonists.
If you’ve ever stared at a pharmacy box and wondered what GLP-1 and GIP meaning really signals, you’re not alone. Once you understand how drug names are built, the box tells you much more than it seems to. This guide walks through the names, the trial acronyms and the mechanism words you’ll run into, so you can tell a single-target drug from a dual or triple agonist.
Two hormones, one shared job
GLP-1 stands for glucagon-like peptide-1, and your intestine releases it after you eat. GIP, short for glucose-dependent insulinotropic polypeptide, comes mostly from the upper part of the small intestine. Both belong to the incretin group. They help your pancreas release insulin, mainly when blood glucose is high.
That glucose dependence is part of why incretin-based drugs carry a lower hypoglycemia risk when they’re used without insulin or sulfonylureas. The catch is speed. An enzyme called DPP-4 breaks down both hormones quickly, so natural levels last only minutes. Drug makers engineered their molecules to resist that enzyme and stay active for much longer.
Decoding the name on the box
Drug names follow the INN system from the World Health Organization, which uses stems to group molecules by family. The stem “-glutide” shows up in GLP-1 analogs such as semaglutide, liraglutide and dulaglutide. Tirzepatide breaks that pattern. Its name doesn’t contain “-glutide,” so nothing in the name tells you it also activates GIP receptors. That’s a useful lesson: a suffix can hint at a mechanism, but it won’t always.
Brand names hide the molecule even further. Ozempic and Wegovy both contain semaglutide, yet they carry different approved indications. Ozempic was approved in the United States for type 2 diabetes in 2017, while Wegovy was approved for chronic weight management in 2021. Mounjaro and Zepbound follow a similar pattern with tirzepatide. Check the current FDA label before you rely on any of these details, since indications can change. When you’re comparing a brand with its molecule, the OzemBlog naming cheat sheet is a handy quick reference for stems and suffixes.
Now the mechanism words. An agonist is a molecule that switches on a receptor. Tirzepatide is a dual agonist, activating both GIP and GLP-1 receptors. Retatrutide goes a step further and targets GIP, GLP-1 and glucagon receptors. It is in phase 3 trials, but it is not approved as of this writing. Treat any claim that it’s already on the shelf as a red flag, and check its status on ClinicalTrials.gov before you trust a headline.
Reading the trial acronyms in headlines
Headlines love acronyms. SURPASS is the tirzepatide program in type 2 diabetes. SURMOUNT is the tirzepatide program in obesity. STEP covers semaglutide for weight management, and SUSTAIN covers semaglutide in type 2 diabetes. Program names are only a starting point, so confirm each one and its primary endpoint on ClinicalTrials.gov or in the sponsor’s publication list.
Once you find the study, look at four things. HbA1c change tells you how much average blood sugar dropped, and it matters most in diabetes studies. Weight results can be reported as a percentage of body weight or as absolute kilograms, and the percentage often sounds bigger for people who started heavier. The placebo comparator shows what happens without the drug, while an active comparator shows how a drug stacks up against another treatment. Finally, check the estimand, which defines who counts in the results. The treatment-regimen estimand counts people as assigned, whether or not they stayed on the drug.
Be careful with cross-trial comparisons. Populations, trial lengths and baseline characteristics differ, so a number from one study rarely maps onto another. Only head-to-head trials allow a direct comparison. SURMOUNT-5 is one such study, comparing tirzepatide with semaglutide in adults with obesity. Read the original paper for its results instead of relying on a summary.
What the GIP part adds, and what’s still unclear
GIP receptors appear in fat tissue, pancreatic islets and the brain. Researchers have proposed several roles for GIP in fat metabolism and nausea, but the evidence is still mixed. Treat those ideas as hypotheses rather than settled mechanisms.
Some pipeline drugs take the opposite route. Maridebart cafraglutide, for example, activates GLP-1 receptors while blocking the GIP receptor. It is investigational and not approved, so look at its entry on ClinicalTrials.gov before drawing conclusions.
It’s tempting to assume that dual agonists are always better. The honest answer depends on the outcome you measure, the dose, how well you tolerate the drug and your own health profile. A result that looks impressive in one population may not carry over to yours.
Reading the leaflet and the pharmacy label
The indications section and the dosing frequency in the leaflet tell you more than the brand name does. Weekly injections and daily oral forms of GLP-1 drugs both exist, and their labels differ in dosing, storage and device instructions. Read the approved use first, then match it to why your doctor prescribed the drug.
In Brazil, look for the ANVISA registration number on the product. A compounded preparation carries a different label and prescription format, so the paperwork itself can be a clue. Keep your focus on the label, and leave counterfeit detection to our existing posts on fake pens.
When you pick up a medicine, compare the leaflet with what the pharmacy handed over, using the OzemBlog reading checklist to confirm that the name, strength and frequency all match.
Common mix-ups that lead to dosing mistakes
Milligram doses don’t carry across drugs. A tirzepatide dose and a semaglutide dose do not correspond one to one, so never convert one into the other on your own. Quote dose ranges only from the current label, and verify them with your prescriber. Watch out for these common traps:
- Assuming a milligram number means the same thing across different molecules.
- Treating a supplement labeled “GLP-1” as if it were an incretin medicine. Those products aren’t drugs and don’t act like them. Our natural GLP-1 post covers that theme in more detail.
- Believing every weekly pen works the same way. Injection devices, needle sizes and storage rules differ between products.
- Skipping the leaflet because the pen looks familiar.
Before your next appointment, bookmark OzemBlog’s drug name guide so you can check a name against its molecule before you ask about a dose change.
FAQ
Is GLP-1 the same as GIP?
No. Both are incretin hormones from the gut that help release insulin when glucose is high, but they act on different receptors and come from different parts of the intestine.
Why doesn’t the name tirzepatide show that it targets GIP?
The INN system uses stems to group molecules by family, and tirzepatide doesn’t carry the “-glutide” stem used for GLP-1 analogs. The name alone doesn’t reveal every mechanism, so check the prescribing information.
Is retatrutide available yet?
Not as of this writing. Retatrutide is in phase 3 trials, and its status should be checked on ClinicalTrials.gov before you rely on any claim about availability.
Can I compare two drugs using their headline numbers?
Usually not. Cross-trial comparisons are unreliable because populations, durations and baselines differ. Head-to-head trials are the only direct comparison.
Sources
Disclaimer: This content is for informational purposes only and does not replace professional medical advice. Always consult your doctor before starting, changing or stopping any treatment.
Ozempro — Monitor GLP-1
Never miss a dose and track everything
Injection reminders, a dose history and a side-effects diary — all organized to bring to your appointment.
or download the app
